This Rare 'Silent' Cancer Has Quadrupled Among Millennials
A new study, published this week in the Annals of Internal Medicine, found that a rare form of cancer – appendix cancer, or appendiceal adenocarcinoma – is as much as three times as common among Gen X, born between 1965 and 1980, as it is among those born in the '40s.
However, for older millennials who were born in the '80s (millennials were born between 1981-1996), the rates were more than four times higher.
The Christie NHS Foundation Trust explains it accounts for 0.4% of all cancers of the bowel; it's a rare condition.
But what is appendix cancer, how do you spot it, and why might it be on the rise?
Appendiceal adenocarcinoma, the most common form of appendix cancer, can often develop 'without developing symptoms,' the Cleveland Clinic shares.
Because it can be so hard to spot, it is sometimes described as a 'silent' cancer in its early stages.
Often, people only notice signs when the tumours have spread; the NHS say that it is often only spotted during surgery.
Some symptoms that may occur, however, include:
Appendicitis
Bloating
A buildup of fluid in your abdomen
An increased waist size
Abdominal or pelvic pain.
Changes in bowel habits (including diarrhoea)
Nausea and vomiting
Feeling full soon after you start eating.
Speak to your GP immediately if you notice signs of appendix cancer.
This study did not seek to find out why different generations have different rates of appendix cancer.
But it is not the only cancer which has followed a similar generational pattern – bowel and breast cancer, for instance, are both affecting more and more young people while rates among older people stay roughly stable.
Speaking to the New York Times, gastroenterologist and colon cancer expert Dr Andrew T. Chan, who was not involved in the study, suggested that some changes to our diet over time might be responsible for the uptick in bowel cancers.
But it is hard to say more about appendix cancer, which is already a poorly understood condition.
Cancer expert Professor Andreana Holowaty told the publication that the rise does not seem to be caused by an increase in diagnoses, however, not least because the disease is so hard to spot.
'Similar trends have been reported for other gastrointestinal cancers, suggestive of a potential shared cause contributing to this increasing cancer burden across generations,' the paper reads.
Scientists' Bowel Cancer Breakthrough 'Pivotal' For Future Treatment
These 3 Diet Changes May Reduce Your Bowel Cancer Risk By 47%
The Nutrient Linked To Lower Cancer, Heart Disease, And Dementia Risk
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vogue
4 hours ago
- Vogue
Everything You Need to Know About the New Breast Cancer Vaccine
In the search for a cure for breast cancer, a major breakthrough has finally come. Biotechnology company Anixa Biosciences, Inc. announced earlier this month that its breast cancer vaccine, which is being designed with the help of the Cleveland Clinic, has completed phase 1 of its clinical testing. It will be moving forward to the next stages of development, and if all goes to plan, doctors may soon be able to stop cancerous tumors from forming. 'The vaccine is designed to mobilize the patient's immune system to find, recognize, and destroy breast cancer cells for primary prevention,' Amit Kumar, Ph.D, CEO of Anixa Biosciences, Inc., tells Vogue. 'If a patient is vaccinated and [their] immune system is trained to destroy the cancer cells when the cancer appears, the vaccinated immune system will destroy the cells before they can grow into a cell tumor.' The vaccine, which comes in a set of three shots given to patients two weeks apart, specifically targets alpha-lactalbumin, a milk protein that is produced during lactation. It is typically not found after lactation in normal breast tissue, but scientists have found that the protein is expressed in about 70% of triple-negative breast cancer (TNBC) cases. The hope, Rima Patel, MD, oncologist and assistant professor in the division of hematology and medical oncology at Mount Sinai, explains, is that the vaccine can train people's immune system to recognize the protein as harmful and attack it before it turns into cancer. 'It is designed to alert the immune system to attack a breast tumor, before it can develop or recur, and prevent it from growing,' says Dr. Patel. 'It has been studied in an early phase 1 clinical trial in 35 women who had a history of early-stage TNBC and are at high risk of recurrence, and in patients without a history of cancer but are at high risk of developing breast cancer due to a genetic predisposition or other factors. The study thus far showed that the vaccine is overall well tolerated and resulted in an immune response in most patients.' Research in mice shows that the vaccine has been successful in activating the immune system against alpha-lactalbumin and preventing breast tumors in these small creatures. While the vaccine shows promise in humans, Dr. Kumar says they have to test larger numbers and with control groups in the next phases to show its efficacy and safety.
Chicago Tribune
7 hours ago
- Chicago Tribune
Mattress toppers that ease hip pain
It's true that as you get older, you get wiser, but you know what else comes with age? Aches and pains. Hip pain is one of those issues that not only affects your daytime routine but also makes it difficult to get quality sleep, which is something everyone needs. Luckily, mattress toppers can help decrease hip pain and send you to dreamland with ease. How do you know which one to buy? We've broken down everything from what exactly causes hip pain to what to look for in a mattress topper, and of course, included some of our top this type of body ache is fairly common. According to the Cleveland Clinic, it could be a symptom of arthritis, bursitis, hip injuries or even structural issues. While a mattress topper won't fix hip pain, it can offer pressure relief and improve your quality of sleep without needing to purchase a new mattress. It helps with contouring, as it molds to your hips and redistributes your weight, which takes the pressure off the joints. If you love to sleep on your side, go for a thicker topper with more material to support your hip. If you're a stomach sleeper, opt for a thinner version, so your back alignment doesn't add more pressure to your hip joints. The firmness of your mattress topper depends to some degree on your weight. Individuals who weigh more should opt for a firmer product for added support; those who weigh less can consider a softer memory foam version. You can combine the firmness of your actual mattress with the firmness of your topper for the perfect feel. The firmer the mattress, the softer the topper and vice versa. When you buy a mattress topper, it's important to consider ventilation to ensure proper heat distribution, motion isolation, especially if your partner moves in their sleep, whether or not you want gel memory foam — which also helps with cooling — and customizable options that'll give the perfect mattress topper for your needs. Sleep Innovations Dual-Layer 4-Inch Memory Foam Mattress Topper This one works well for all types of sleepers, as it offers medium support. It comes with 2 inches of gel topped by 2 inches of a pillow-like material and isn't textured, making it great for sensitive skin. Tempur-Pedic TEMPUR-Adapt + Cooling 3-Inch Mattress Topper If you want to splurge on your purchase, this is a great choice. It has 3 inches of exclusive TEMPUR-ES material, a washable cooling cover, is easy to take on and off and comes with a 10-year warranty. Pure Green Natural Latex Mattress Topper This is a best bet if you're a conscious shopper. The latex foam on this mattress topper adjusts to your body instantly, is Fair Trade certified and made from organically grown rubber trees. Lucid Ventilated Gel Memory Foam Mattress Topper If you want ultra ventilation in your mattress topper, this is the one for you. The gel memory foam captures heat and conforms to your body as you sleep. Since it's a soft topper, however, it's not great for sleepers who are heavier. BestReviews spends thousands of hours researching, analyzing and testing products to recommend the best picks for most consumers. BestReviews and its newspaper partners may earn a commission if you purchase a product through one of our links. Distributed by Tribune Content Agency, LLC.
Yahoo
10 hours ago
- Yahoo
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. 'Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure,' a Novo Nordisk spokesperson told The Independent. 'Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in cardiovascular death, stroke, and myocardial infarction.' A request for comment from Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.
